Katia J Bruxvoort1, Anna S Liang2, Rafael Harpaz3, Lei Qian4, Lina S Sy5, Philip LaRussa6, D Scott Schmid7, Yi Luo8, Harpreet Takhar9, Hung Fu Tseng10. 1. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Katia.Bruxvoort@kp.org. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Shuhua.Liang@kp.org. 3. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: rzh6@cdc.gov. 4. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lei.X.Qian@kp.org. 5. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lina.S.Sy@kp.org. 6. Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York City, NY, United States. Electronic address: plarussa@columbia.edu. 7. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: dss1@cdc.gov. 8. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Yi.X.Luo@kp.org. 9. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Harpreet.S.Takhar@kp.org. 10. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hung-Fu.X.Tseng@kp.org.
Abstract
INTRODUCTION: Pain following herpes zoster (HZ) can persist for months and negatively impact quality of life. To evaluate the effect of zoster vaccine live (ZVL) on progression of pain following HZ, we conducted a prospective cohort study of HZ cases at Kaiser Permanente Southern California. METHODS: ZVL vaccinated and unvaccinated members aged ≥60 years with laboratory-confirmed HZ from January 18, 2012 to February 26, 2015 were followed up within 5 days of HZ diagnosis, and at 30, 60, and 90 days after diagnosis. Pain was assessed with the Zoster Brief Pain Inventory (ZBPI) on a 0-10 scale, using cut-points of ≥3, ≥5, and ≥7, with postherpetic neuralgia (PHN) defined as pain ≥3 at 90 days. Log binomial regression was used to estimate adjusted risk ratios (aRRs) and 95% confidence intervals (CIs) associated with pain, comparing vaccinated versus unvaccinated HZ patients. RESULTS: We interviewed 509 vaccinated and 509 unvaccinated HZ patients. ZVL was associated with significantly lower risks of HZ-related pain at all time-points. The risk of PHN in vaccinated and unvaccinated patients, respectively, was 9.2% and 15.4% (aRR = 0.594, 95% CI: 0.413, 0.854); 2.0% and 4.8% of these patients reported pain ≥7 (aRR = 0.332, 95% CI: 0.153, 0.721). Irrespective of vaccination, the risk of PHN was lower in adults aged <70 years versus those ≥70 years and was similar or lower in females versus males. CONCLUSION: We used laboratory confirmation of HZ cases and patient survey to show that aside from preventing HZ, ZVL reduced HZ-related pain and prevented PHN among vaccine recipients who experienced HZ. Observational studies will be needed to evaluate long-term effectiveness of the new recombinant zoster vaccine and its benefits in protecting patients against PHN.
INTRODUCTION:Pain following herpes zoster (HZ) can persist for months and negatively impact quality of life. To evaluate the effect of zoster vaccine live (ZVL) on progression of pain following HZ, we conducted a prospective cohort study of HZ cases at Kaiser Permanente Southern California. METHODS: ZVL vaccinated and unvaccinated members aged ≥60 years with laboratory-confirmed HZ from January 18, 2012 to February 26, 2015 were followed up within 5 days of HZ diagnosis, and at 30, 60, and 90 days after diagnosis. Pain was assessed with the Zoster Brief Pain Inventory (ZBPI) on a 0-10 scale, using cut-points of ≥3, ≥5, and ≥7, with postherpetic neuralgia (PHN) defined as pain ≥3 at 90 days. Log binomial regression was used to estimate adjusted risk ratios (aRRs) and 95% confidence intervals (CIs) associated with pain, comparing vaccinated versus unvaccinated HZ patients. RESULTS: We interviewed 509 vaccinated and 509 unvaccinated HZ patients. ZVL was associated with significantly lower risks of HZ-related pain at all time-points. The risk of PHN in vaccinated and unvaccinated patients, respectively, was 9.2% and 15.4% (aRR = 0.594, 95% CI: 0.413, 0.854); 2.0% and 4.8% of these patients reported pain ≥7 (aRR = 0.332, 95% CI: 0.153, 0.721). Irrespective of vaccination, the risk of PHN was lower in adults aged <70 years versus those ≥70 years and was similar or lower in females versus males. CONCLUSION: We used laboratory confirmation of HZ cases and patient survey to show that aside from preventing HZ, ZVL reduced HZ-related pain and prevented PHN among vaccine recipients who experienced HZ. Observational studies will be needed to evaluate long-term effectiveness of the new recombinant zoster vaccine and its benefits in protecting patients against PHN.
Authors: Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi Journal: CMAJ Date: 2010-10-04 Impact factor: 8.262
Authors: Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin Journal: Clin Infect Dis Date: 2004-07-19 Impact factor: 9.079
Authors: Jessica Leung; Rafael Harpaz; Andrew L Baughman; Karl Heath; Vladimir Loparev; Marietta Vázquez; Barbara M Watson; D Scott Schmid Journal: Clin Infect Dis Date: 2010-07-01 Impact factor: 9.079
Authors: M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: Ralph P Insinga; Robbin F Itzler; James M Pellissier; Patricia Saddier; Alexander A Nikas Journal: J Gen Intern Med Date: 2005-08 Impact factor: 5.128
Authors: Kenneth E Schmader; Richard Sloane; Carl Pieper; Paul M Coplan; Alexander Nikas; Patricia Saddier; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Heather M Williams; Michael N Oxman Journal: Clin J Pain Date: 2007 Jul-Aug Impact factor: 3.442
Authors: Paul M Coplan; Kenneth Schmader; Alexander Nikas; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Mark Bauer; Heather M Williams; Karen M Kaplan; Harry A Guess; Michael N Oxman Journal: J Pain Date: 2004-08 Impact factor: 5.820
Authors: Robert H Dworkin; John W Gnann; Anne Louise Oaklander; Srinivasa N Raja; Kenneth E Schmader; Richard J Whitley Journal: J Pain Date: 2008-01 Impact factor: 5.820
Authors: Hilary C Tanenbaum; Anna Lawless; Lina S Sy; Vennis Hong; Bradley Ackerson; Katia Bruxvoort; Yi Luo; Hung Fu Tseng Journal: J Pain Res Date: 2020-07-13 Impact factor: 3.133
Authors: Hantong Hu; Yejing Shen; Xinwei Li; Hongfang Tian; XingLing Li; Yang Li; Yingying Cheng; Lei Wu; Dexiong Han Journal: Front Med (Lausanne) Date: 2021-05-21